Form D · Biotechnology

Biotie Therapies Corp.

Turku, H9 · CIK 0001579695

Offering snapshot reported Jun 2, 2015 · SEC filing

Reported sold
$6.06M
Offering amount: $16.3M
Investors reported
4
Form D · investor count
Minimum accepted
$545K
Reported outside-investor minimum
First sale
May 28, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 2, 2015Initial$6,058,176No comparison4SEC filing
Jun 26, 2013Initial$143,750,000No comparison44SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$424K
Finders' fees
$0
Form D file number
021-240976
Amounts in Item 11 and Item 13 use an exchange rate of EUR 1 to USD 1.0896 (as reported by the ECB on May 28, 2015). Total Remaining to be sold: Subscription period has closed therefore no securities remain to be sold.
*Exchange rate of EUR 1 to USD 1.0896 (as reported by the ECB on May 28, 2015)

Source: Form D, filed Jun 2, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Don Matthew Bailey Director
Stephen Bandak Executive
Williams Burns Director
William Burns Director
David Cook Executive
Peter Fellner Director
Merja Karhapaa Director
Bernd Kastler Director
Ismail Kola Director
Guido Magni Director
Ian Massey Executive
Medhi Paborji Executive
Mahendra G Shah Director
Timo Veromaa Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Joukahaisenkatu 6
Turku, H9, FI-20520